Five manufacturing buildings, a quality control building, an office building, and a wastewater treatment facility are all included! It has a manufacturing license for pharmaceuticals.
Tateyama Kasei Co., Ltd.'s Kyushu factory is located in Tagawa City, which is situated in the central part of Fukuoka Prefecture. It began operations in 1972 and is equipped with five manufacturing buildings, a quality control building, an office building, and wastewater treatment facilities. Notable equipment includes an indirect cooling type ultra-low temperature reaction device and a filtration dryer. The factory holds a manufacturing license for pharmaceuticals and has two lines of 6000L active pharmaceutical ingredient purification equipment, making it suitable for the production of relatively large quantities of stable active pharmaceutical ingredients. [Features] - Possesses an indirect cooling type ultra-low temperature reaction device and a filtration dryer - Holds a manufacturing license for pharmaceuticals - Well-suited for the production of relatively large quantities of stable active pharmaceutical ingredients *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Production Equipment (Excerpt)】 ■Site Area: 15,300m2 ■Centrifuge: 32–48 inch (SUS×5, RL×1, Hastelloy×1) ■Concentration Equipment: Thin-Film Evaporator ×2 ■Low-Temperature Reaction Equipment: 2,400L SUS×1 ■Hydrogen Reduction Equipment: 650L SUS×1 (10kgf/cm2) ■Grinder: Pin Mill ×2, Cutter Mill ×1 ■Clean Room (Class 100,000): 6,000L×2 (GL) *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
We, Tateyama Kasei Co., Ltd., started our production in 1953 with methyl ephedrine. Currently, we manufacture a wide range of organic compounds such as pharmaceutical raw materials, pharmaceutical intermediates, and electronic materials under a thorough quality control and quality assurance system backed by ISO 9001 and c-GMP. In 2006, we also experienced an FDA inspection for API manufacturing. As international demands for quality control and assurance continue to rise, we aim to provide truly valuable products to users around the world. Additionally, to protect the global environment, we are enhancing efficient production technologies and appropriate pollution control facilities, while considering safety, health, and environmental conservation. We are always focused on quality, responsiveness, and the environment, with the development of high value-added products as our top priority for further growth.
![[CPhI Seminar Report] Mutagenic Impurities in Pharmaceuticals (Active Pharmaceutical Ingredients)](https://image.mono.ipros.com/public/product/image/86f/2000714763/IPROS54094091646706511898.png?w=280&h=280)
